HLB to Present Research Poster on Rivoceranib at ESMO Next Month

HLB will unveil multiple research results related to the anticancer drug Rivoceranib, which is seeking approval from the U.S. Food and Drug Administration (FDA), at the European Society for Medical Oncology (ESMO) conference held next month. This year’s ESMO will take place from the 13th to the 17th of next month in Barcelona, Spain. Along with the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR), it is considered one of the world’s top three cancer conferences and the largest cancer academic event in Europe. Among these, it is held last every year and is also regarded as a precursor event to the following year’s JP Morgan Healthcare Conference (JPMHC), the world’s largest platform for technology transfer and investment attraction.

At the 2022 European Society for Medical Oncology (ESMO) held in Paris, France, the Phase 3 clinical trial results of the combination therapy of Lenvatinib and Camrelizumab were unveiled for the first time.
[Photo by HLB]

HLB announced on the 5th that at this ESMO, through its U.S. subsidiary Elevate Therapeutics, it will present sub-analysis results showing that the combination therapy of Rivoceranib and Camrelizumab from Hansoh Pharmaceutical not only demonstrates high therapeutic efficacy in liver cancer patients but also significantly improves patients’ quality of life compared to the control group. Additionally, it will disclose further sub-analysis results from the global phase 3 liver cancer trial, including the analysis of anti-drug antibody (ADA) formation. Safety results of the combination therapy of Rivoceranib and Bristol-Myers Squibb’s (BMS) immuno-oncology drug Nivolumab will also be revealed.

At this ESMO, a total of nine studies related to Rivoceranib will be presented as posters. The cancer types covered include seven cancers: liver cancer, osteosarcoma, cholangiocarcinoma, esophageal cancer, melanoma, undifferentiated thyroid cancer, and ovarian cancer.

The company expects that additional analysis results on quality of life improvement in liver cancer patients treated with the combination therapy of Rivoceranib and Camrelizumab will provide evidence that quality of life can be maintained alongside high therapeutic efficacy. The clinical trial of the Rivoceranib-Camrelizumab combination therapy as neoadjuvant treatment for esophageal cancer patients, which had an interim report at last year’s ASCO, will present its final results at this ESMO.

Besides the combination with Camrelizumab, clinical results of combination therapy with Fuzuloparib, developed by partner Hansoh Pharmaceutical as treatments for ovarian, breast, and prostate cancers, will also be disclosed. Since Rivoceranib and Fuzuloparib have already shown excellent therapeutic effects in platinum-sensitive ovarian cancer patients, efficacy results targeting recurrent ovarian cancer patients are also highly anticipated at this ESMO.

Han Yonghae, CTO of HLB Group, said, "Based on the additional data secured across various cancer types, we will continue to consider global expansion following the approval of the liver cancer treatment."